TPEx-Listed HanchorBio Advances Global Impact of HCB101 Immunotherapy
TAIPEI, SHANGHAI and SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY
Article Date
July 16, 2025
This article is featured on another website.
Go to article
August 26, 2026
Asia’s Shifting Regulatory Map: What Sponsors Need to Know Before Choosing a Trial Location
Part 3 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
August 26, 2026
Asia’s Shifting Regulatory Map: What Sponsors Need to Know Before Choosing a Trial Location
Part 3 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…